Get the Stockscreener App
2.38
4.42%
-0.11
Clearmind Medicine Inc stock is traded at $2.38, with a volume of 37,543.
It is down -4.42% in the last 24 hours and down -8.11% over the past month.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
See More
Previous Close:
$2.49
Open:
$2.44
24h Volume:
37,543
Relative Volume:
0.02
Market Cap:
$3.54M
Revenue:
-
Net Income/Loss:
$-6.64M
P/E Ratio:
-0.0133
EPS:
-179.3009
Net Cash Flow:
$-5.60M
1W Performance:
-22.48%
1M Performance:
-8.11%
6M Performance:
-89.23%
1Y Performance:
-99.33%
1-Day Range:
$2.36
$2.495
1-Week Range:
$2.36
$3.105
52-Week Range:
$2.10
$524.00
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
2.38 | 3.70M | 0 | -6.64M | -5.60M | -179.30 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 121.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 65.01B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.26B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 39.14B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 37.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Clearmind Medicine Inc Stock (CMND) Latest News
Price to earnings forward of Clearmind Medicine Inc. – MUN:CWY0 - TradingView
Price to earnings forward of Clearmind Medicine Inc. – NASDAQ:CMND - TradingView
Enterprise value to revenue forward of Clearmind Medicine Inc. – NASDAQ:CMND - TradingView
Clearmind Medicine Company Profile & Introduction - Moomoo
Price to sales forward of Clearmind Medicine Inc. – NASDAQ:CMND - TradingView
Price to book forward of Clearmind Medicine Inc. – NASDAQ:CMND - TradingView
Clearmind Medicine Reaches Major Milestone, Completing Part a Treatment in FDA-Regulated Phase I/II Trial - marketscreener.com
Clearmind Medicine Inc (CMND) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Clearmind completes treatment phase of alcohol disorder trial - Investing.com UK
Clearmind Medicine (CMND) Completes Phase I/II Trial for Alcohol Use Disorder - GuruFocus
Clearmind Medicine Completes Treatment for All Participants in Part A of Phase I/II Trial of CMND-100 for Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial - The Manila Times
Clearmind finishes 24-patient AUD trial stage; next phase awaits data review - Stock Titan
Insider Selling: Financial Hrt Sells Shares of Clearmind Medicine Inc (CMND) - GuruFocus
HRT Financial LP trims Clearmind Medicine (CMND) stake with 22,139-share sale - Stock Titan
Clearmind Medicine receives U.S. patent for binge behavior treatment - Investing.com
Clearmind Medicine receives U.S. patent for binge behavior treatment By Investing.com - Investing.com India
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators - The Manila Times
Clearmind Medicine (NASDAQ: CMND) secures U.S. patent for MEAI binge behavior regulators - Stock Titan
Clearmind Medicine Inc Share PriceCMND, RNS News, Articles, Quotes, & Charts (NASDAQ:CMND) - Proactive financial news
symbol__ Stock Quote Price and Forecast - CNN
Insider Sell: Financial Hrt Reduces Stake in Clearmind Medicine Inc (CMND) - GuruFocus
Clearmind Medicine Inc (CMND) Institutional Confidence - TradingKey
Clearmind Medicine Inc (CMND) Valuation: PE, PB & Fair Value Analysis - TradingKey
Clearmind Medicine Inc (CMND) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Clearmind Medicine (CMND) holder HRT Financial LP sells 3,183 shares - Stock Titan
Clearmind Medicine Inc (CMND) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Clearmind Medicine Inc (CMND) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Clearmind Medicine Inc (CMND) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Clearmind Medicine Inc (CMND) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Clearmind Medicine Inc (CMND) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Clearmind completes dosing for phase I/II alcohol disorder trial By Investing.com - Investing.com South Africa
Clearmind Medicine finishes dosing 24 trial participants - grafa.com
Clearmind completes dosing for phase I/II alcohol disorder trial - Investing.com UK
HRT Financial LP trims Clearmind Medicine (CMND) stake with 2,102-share sale - Stock Titan
Clearmind Medicine Completes Dosing For Part A Of Its Of FDA-Regulated Phase I/Ii Clinical Trial - TradingView
Clearmind Medicine Inc. Successfully Completes Dosing in Phase I/II Clinical Trial for CMND-100 to Treat Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine (NASDAQ: CMND) finishes Part A dosing in CMND-100 Alcohol Use Disorder trial - Stock Titan
Experimental alcohol addiction drug completes first-stage testing - Stock Titan
Clearmind Medicine | 6-K: Report of foreign private issuer (related to financial reporting) - Moomoo
Cash per share of Clearmind Medicine Inc. – FWB:CWY0 - TradingView
Tangible book value per share of Clearmind Medicine Inc. – FWB:CWY0 - TradingView
HRT Financial LP reports 101,951 CMND shares as ten percent owner - Stock Titan
Clearmind Medicine Jumps 24.1% as Traders React to Fresh CMND-100 Updates and Upcoming June 10 Webinar - Moomoo
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Clearmind Medicine Inc. - MLQ.ai
Clearmind Medicine jumps 24.1% as traders react to fresh CMND-100 updates and upcoming June 10 webinar - Quiver Quantitative
CMND Stock Jumps As Clearmind Wins Key Trial, IP Milestones - StocksToTrade
CMND Stock Jumps As Clearmind Advances Trials And Expands IP - timothysykes.com
$Clearmind Medicine (CMND.US)$ - Moomoo
Clearmind Medicine to Present CMND-100 Clinical Trial Data on June 5, 2026 - geneonline.com
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):